ArticleBMJ open2026
Psychometric properties of the Generalised Anxiety Disorder-7 (GAD-7) screening tool in people living with HIV: the Afaan Oromoo version.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of the study was to assess the psychometric properties of the Afaan Oromoo version of Generalised Anxiety Disorder-7 (GAD-7) scale among people living with HIV.
designA hospital-based cross-sectional study.
settingThe study was conducted at a tertiary-level antiretroviral therapy clinic.
participantsThe study included 163 people living with HIV. PRIMARY OUTCOME MEASURES: The GAD-7 scale was evaluated against the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnostic criteria for GAD as the gold standard.
resultA total of 163 participants were enrolled (response rate: 98.2%). The Afaan Oromoo GAD-7 demonstrated excellent internal consistency (Cronbach's alpha=0.92). A cut-off score of ≥9 provided the optimal balance between sensitivity (89.19%) and specificity (85.75%), with an area under curve of 0.91, a positive predictive value of 64.7% and negative predictive value of 96.4%. Confirmatory factor analysis supported a one-factor structure.
conclusionsThe findings indicate that the Afaan Oromoo version of the GAD-7 is a valid and reliable tool for screening GAD among adults receiving HIV care. Routine use of the GAD-7 in antiretroviral therapy clinics is recommended to support early identification of anxiety symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.